Skip to main content
. 2018 Oct 30;246(4):447–458. doi: 10.1002/path.5152

Figure 4.

PATH-5152-FIG-0004-c

Blocking of the PDGF receptor signaling axis has therapeutic value. (A) Growth curves of VM+ (C8161) and VM− (OCM‐1) xenograft tumors treated with or without the PDGF receptor inhibitor imatinib (STI‐571). *p < 0.05, two‐way ANOVA. (B) Double staining for the endothelial cell marker CD31 (brown) and the pericyte marker αSMA (blue) in tumor tissues from VM+ (C8161) and VM− (OCM‐1) xenograft tumors treated with or without the PDGF receptor inhibitor (STI‐571). The bar charts show quantification of blood vessels (CD31+) associated with (αSMA+) or without (αSMA−) perivascular cells. (C) Similar to B for characteristics of VM, i.e. blood lakes and perivascular cells not associated with blood vessels (CD31−/αSMA+). *p < 0.05, Student's t‐test. (D) Quantification of blood lakes, microvessel density (MVD), blood vessels associated with perivascular cells (CD31+/αSMA+), and perivascular cells not associated with blood vessels (CD31−/αSMA+), respectively, in VM+ xenograft tumors treated with STI‐571, anti‐PDGFRα antibody or anti‐PDGFRβ antibody. *p < 0.05, one‐way ANOVA.